Research Topics
Species | Mar TintoreSummaryAffiliation: Hospital Universitari Vall d'Hebron Country: Spain Publications
| Collaborators
|
Detail Information
Publications
Rationale for early intervention with immunomodulatory treatmentsMar Tintore
Unitat de Neuroimmunologia Clinica UNIC, Edif Escola d Infermeria Planta 2, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
J Neurol 255:37-43. 2008..It is concluded that choosing the right time to introduce treatment is critically important for outcome and the earlier treatment is initiated, the better the outcome...- New treatment measurements for treatment effects on relapses and progressionMar Tintore
Unitat de Neuroimmunologia Clinica, Multiple Sclerosis Centre of Catalonia CEM Cat Hospital Vall d Hebron, Barcelona, Spain
J Neurol Sci 274:80-3. 2008..MRI has also been of great help in monitoring the effect of immunomodulatory drugs in CIS or RRMS clinical trials. Its role to predict treatment response is still controversial on an individual basis... 
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?M Tintore
Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
Neurology 70:1079-83. 2008..To evaluate whether oligoclonal bands (OB) add information to MRI in predicting both a second attack and development of disability in patients with clinically isolated syndromes (CIS)...- Brainstem lesions in clinically isolated syndromesM Tintore
Unitat de Neuroimmunologia Clinica UNIC, Edif Escola d Infermeria Planta 2, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
Neurology 75:1933-8. 2010..Number of baseline lesions has been shown to predict future attacks and disability in clinically isolated syndromes (CIS)... - New options for early treatment of multiple sclerosisMar Tintore
Multiple Sclerosis Center of Catalonia, Clinical Neuroimmunology Multiple Sclerosis Unit, Vall d Hebron University Hospital, Barcelona, Spain
J Neurol Sci 277:S9-S11. 2009..An application for an extension of the approved indication of glatiramer acetate to the treatment of patients with a first clinical event suggestive of multiple sclerosis has been filed with the regulatory authorities... - Baseline MRI predicts future attacks and disability in clinically isolated syndromesM Tintore
Unit of Clinical Neuroimmunology Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
Neurology 67:968-72. 2006..To determine the relation between baseline MRI and both conversion to multiple sclerosis (MS) and development of disability in a cohort of patients with clinically isolated syndromes (CIS)... - Early MS treatmentM Tintore
Clinical Neuroimmunology Unit, Vall d Hebron University Hospital, 08035 Barcelona, Spain
Int MS J 14:5-10. 2007..While MRI can be used to determine who will benefit most from treatment, the use of other biological markers needs to be confirmed in different settings before they can be used in clinical practice... - Is optic neuritis more benign than other first attacks in multiple sclerosis?Mar Tintore
Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
Ann Neurol 57:210-5. 2005..Optic neuritis has a smaller risk for conversion to multiple sclerosis. Nevertheless, MRI at baseline, not CIS topography, appears to be the crucial issue at multiple sclerosis presentation... - Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patientsJordi Rio
2TM planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
Ann Neurol 59:344-52. 2006..Early identification of nonresponder patients is crucial to try different therapeutic approaches. We investigated various criteria of treatment response to assess which criterion better identifies patients with a poor response... - Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decisionCarmen Tur
Clinical Neuroimmunology Unit, Multiple Sclerosis Centre of Catalonia Centre d Esclerosi Múltiple de Catalunya, CEM Cat, Vall d Hebron University Hospital, Barcelona, Spain
Mult Scler 18:1193-6. 2012..The decision to discontinue natalizumab treatment is complex, even when clear PML risk rates are described. Clinical outcomes and doctors' idiosyncrasies play a crucial part in patients' final choice... - Interferon beta in secondary progressive multiple sclerosis : daily clinical practiceJordi Rio
2a planta EUI, Unitat de Neuroimmunología Clínica Hospital Universitario Vall d Hebron, Psg Vall d Hebron 119 120, 08035 Barcelona, Spain
J Neurol 254:849-53. 2007..We present the data from a cohort of secondary progressive multiple sclerosis (SPMS) patients treated with interferon beta (IFNbeta-1b) at our MS clinic... - Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromesJaume Sastre-Garriga
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
Arch Neurol 61:222-4. 2004.... - Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centreJordi Rio
2a planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Psg Vall d Hebron 119 120, 08035, Barcelona, Spain
J Neurol 252:795-800. 2005..We present the data of our cohort of relapsing-remitting multiple sclerosis (RRMS) patients treated with interferon beta (IFNbeta)... - Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosteroneNieves Téllez
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, 08035 Barcelona, Spain
Mult Scler 12:487-94. 2006..Fatigue is one of the most limiting symptoms in multiple sclerosis (MS) and the mechanisms underlying its origin are poorly understood. Our aim was to test whether fatigue in MS is associated with endocrine markers... - Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosisJordi Rio
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
Mult Scler 11:306-9. 2005.... - Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosisManuel Comabella
Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona 08035, Spain
Brain 133:1082-93. 2010.... - Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trialsJordi Rio
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
Ann Neurol 52:400-6. 2002.... - A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosisAlex Rovira
Magnetic Resonance Unit, Department of Radiology, Hospital Vall d Hebron, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
Arch Neurol 66:587-92. 2009.... - [Long-term effect of neutralizing antibodies to interferon beta-1 b in patients with multiple sclerosis]Jordi Rio
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
Med Clin (Barc) 124:140-1. 2005..Our goal was to evaluate the relation between the presence of neutralizing antibodies (NABs) to interferon beta-1b in multiple sclerosis (MS) patients and the clinical evolution in the following years... - The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-betaPablo Villoslada
Neuroimmunology Unit, Hospital Vall d'Hebron, Barcelona, Spain
J Neuroimmunol 130:194-201. 2002..Similarly, no difference in the distribution of responders and nonresponders to interferon-beta (IFNB) therapy, as defined by primary and secondary end points, was observed when individuals were stratified according to HLA-DR2 status... - Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-upCarmen Tur
Multiple Sclerosis Centre of Catalonia, Autonomous University of Barcelona, Centre d Anàlisi i Recerca en Neuroimatge i Esclerosi Mùltiple Vall d Hebron University Hospital, Escola Universitària d Infermeria 2ª planta, Passeig de la Vall d Hebron 119 129, 08035 Barcelona, Spain
Arch Neurol 68:1421-7. 2011.... - B cell expression of the inhibitory Fc gamma receptor is unchanged in early MSManuel Comabella
Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
J Neuroimmunol 223:135-7. 2010.... - The immune response against herpesvirus is more prominent in the early stages of MSP Villoslada
Neuroimmunology Unit, Hospital Vall d Hebron, Barcelona, Spain
Neurology 60:1944-8. 2003..To assess antibody levels against human herpesvirus type 6 (HHV-6), Epstein-Barr virus (EBV), and Chlamydia pneumoniae (CP) in serum from individuals in the early and late phase of MS... - Altered maturation of circulating dendritic cells in primary progressive MS patientsCristina Lopez
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, HUVH, Barcelona, Spain
J Neuroimmunol 175:183-91. 2006..These results suggest an impaired maturation state of DC in PPMS patients, and a beneficial effect of IFN-beta favouring the survival of PDC and promoting a Th2 environment... - Unconventional therapy in multiple sclerosisJaume Sastre-Garriga
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
Mult Scler 9:320-2. 2003..The use of unconventional therapies is growing in western countries. Few studies on their frequency and rationale among multiple sclerosis (MS) patients have been carried out in Europe... - Decreased MMP-9 production in primary progressive multiple sclerosis patientsJ Sastre-Garriga
Unitat de Neuroimmunologia Clinica, Hospital Vail d Hebron, Barcelona, Espanya
Mult Scler 10:376-80. 2004..However, data regarding primary progressive (PP) MS is scarce... - Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?R Pelayo
Multiple Sclerosis Center of Catalonia, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
Mult Scler 16:55-61. 2010..However, the utility of MMEPs is limited by the low percentage of CIS patients having the three abnormal at baseline... - A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosisX Montalban
Unitat de Neuroimmunologia Clinica, Multiple Sclerosis Centre of Catalonia CEM Cat, Barcelona, Spain
Mult Scler 15:1195-205. 2009..Positive effects of interferon beta on secondary clinical and magnetic resonance imaging outcomes were observed, but a beneficial effect on Expanded Disability Status Scale progression was not demonstrated... - Serial proton spectroscopy, magnetization transfer ratio and T 2 relaxation in pseudotumoral demyelinating lesionsM Gràcia Cucurella
Unitat de Ressonància Magnètica Vall d Hebron, Institut de Diagnostic per la Imatge, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
NMR Biomed 15:284-92. 2002..Thus, the evolution of this kind of lesion should be kept in mind when considering lesion volume from T1-weighted images as a marker of disability or irreversible cellular destruction in MS... - Multiple sclerosis: Lesion location may predict disability in multiple sclerosisJaume Sastre-Garriga
Centre d esclerosi multiple de Catalunya, Hospital Universitari Vall d Hebron, Passeig de la Vall d Hebron 119 129, Barcelona, Spain
Nat Rev Neurol 6:648-9. 2010..Using a lesion probability mapping approach, researchers have identified brain regions where the presence of MS lesions predicts an early need for bilateral walking support... - Early onset multiple sclerosis: the role of genderMar Tintore
Multiple Sclerosis Center of Catalonia, Clinical Neuroimmunology Multiple Sclerosis Unit, Vall d Hebron University Hospital, Barcelona, Spain
J Neurol Sci 286:31-4. 2009..Sex hormones may have immunologic implications, but more data are needed to explain the female predominance and its changes over time... - The basal ganglia: a substrate for fatigue in multiple sclerosisN Tellez
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
Neuroradiology 50:17-23. 2008..We aimed to study the relationship between fatigue in MS and the presence of focal dysfunction in the basal ganglia and frontal white matter... - [Multiple sclerosis epidemiological situation update: pertinence and set-up of a population based registry of new cases in Catalonia]S Otero
Servicio de Medicina Preventiva y Epidemiologia, Hospital General Universitari Vall d Hebron, Barcelona, Espana
Rev Neurol 50:623-33. 2010..The few prospective studies in our area together with the increase in the disease in other regions, justifies an epidemiological MS project in order to describe the incidence and temporal trends of MS... - Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohortR Pelayo
Department of Neurology, Unit of Clinical Neuroinmunology, Hospital Universitari Vall d Hebron, Universitat Autonoma UAB, Barcelona, Spain
Mult Scler 13:731-6. 2007..There are differences between several studies in the definition, and, therefore, the prevalence of these so-called atypical CIS. Consensus on the denomination and definition of these syndromes must be reached... - Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?N Tellez
Unitat de Neuroimmunologia Clinica, Edif EUI, Planta 2, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, 08035 Barcelona, Spain
Mult Scler 11:198-202. 2005..As a symptom of multiple sclerosis (MS), fatigue is difficult to manage because of its unknown etiology, the lack of efficacy of the drugs tested to date and the absence of consensus about which would be the ideal measure to assess fatigue... - Fatigue in multiple sclerosis persists over time: a longitudinal studyN Tellez
2a planta EUI Unitat de Neuroimmunología, Clínica Hospital, Universitari Vall d Hebron Ps, Vall d Hebron 119 120, 08035, Barcelona, Spain
J Neurol 253:1466-70. 2006..The aim of our study was to investigate changes in fatigue in a large cohort of MS patients and to determine the relationship between changes in disability and depression with changes in fatigue severity... - Long-term emotional state of multiple sclerosis patients treated with interferon betaJ Porcel
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vail d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
Mult Scler 12:802-7. 2006..To assess the long-term emotional state of multiple sclerosis (MS) patients treated with interferon beta (IFNbeta) for at least four years... - Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosisManuel Comabella
Unitat de Neuroimmunologia Clinica, Edif EUI 2a planta, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
J Neurol 255:1136-41. 2008.... - Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patientsJ Rio
Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
Mult Scler 14:479-84. 2008.... - Measures in the first year of therapy predict the response to interferon beta in MSJ Rio
Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
Mult Scler 15:848-53. 2009..Hence, the aim of this study was to investigate magnetic resonance imaging (MRI) and clinical predictors of response during the first 12 months of therapy... - FXTAS in spanish patients with ataxia: support for female FMR1 premutation screeningLaia Rodriguez-Revenga
Biochemistry and Molecular Genetics Department, Hospital Clinic, Barcelona, Spain
Mol Neurobiol 35:324-8. 2007..Early diagnosis of these patients benefits not only them but also the rest of the family that should be advised for the fragile X syndrome... - New diagnostic criteria for multiple sclerosis: application in first demyelinating episodeM Tintore
Clinical Neuroimmunology Unit, Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
Neurology 60:27-30. 2003.... - MRI criteria for MS in patients with clinically isolated syndromesX Montalban
Unit of Clinical Neuroimmunology, EUI 2 P, Hospital Universitari Vall d Hebron, Paseig Vall d Hebron 119 129, 08035 Barcelona, Spain
Neurology 74:427-34. 2010..New data that are now published were reviewed and discussed and together with a new proposal are integrated in this position paper... - Very early scans for demonstrating dissemination in time in multiple sclerosisC Tur
Clinical Neuroimmunology Unit, Vall d Hebron University Hospital, Barcelona, Spain
Mult Scler 14:631-5. 2008.... - Clinical features of CIS of the brainstem/cerebellum of the kind seen in MSJaume Sastre-Garriga
Unitat de Neuroimmunologia Clinica, MS Centre of Catalonia, Hospital Universitari Vall d Hebron, EUI 2a planta, Passeig de la Vall d Hebron 119 129, 08035 Barcelona, Spain
J Neurol 257:742-6. 2010..Results indicate that diplopia, facial sensory symptoms and gait disturbance occur in more than 30% of patients with CISB. Facial sensory symptoms are less associated with conversion to CDMS... - Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findingsJ Sastre-Garriga
Unitat de Neuroimmunologia Clinica, Hospital Vall d Hebron, Escola d Infermeria, Barcelona, Espana
Mult Scler 9:39-43. 2003..The aim of this study was to investigate conversion to MS in patients with CISB... - [Acute disseminated encephalomyelitis: study of factors involved in a possible development towards multiple sclerosis]C Tur
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona
Neurologia 23:546-54. 2008..Our work supports that also observed in recent publications: that both conversion to MS or presence of sequelae after an episode of ADEM are more frequent than traditionally considered... - Expression of chemokine receptors in the different clinical forms of multiple sclerosisE M Martínez-Cáceres
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
Mult Scler 8:390-5. 2002..These results support that chemokines and their receptors are involved in the pathogenesis of MS However, a pattem of chemokine-chemokine receptor expression characteristic of each clinical form of the disease failed to be observed... - Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosisI Pericot
Unitat de Neuroimmunologia Clinica, Escola d enfermeria, Hospital Universitari Vall d Hebron, Barcelona, Spain
Mult Scler 9:256-9. 2003..The relationship between multiple sclerosis (MS) and Sjögren syndrome (SS) is controversial. Nine patients, previously diagnosed with primary progressive MS (PPMS) and who fulfilled the diagnostic criteria for SS, are described...